Bio Similars/Subsequ ent Entry Biologic
Market
Bio Similars/Subsequent Entry Biologic Market
Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Bio Similars/Subsequent Entry Biologic Market Size and Growth
The global Bio Similars/Subsequent Entry Biologic market is experiencing steady growth due to the increasing demand for cost-effective alternatives to biologic drugs. Key players in the market are investing in research and development to expand their product portfolios. The market size is expected to reach $XX billion by 2025.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Sun Pharma
◍ Synthon Pharmaceuticals
◍ Teva Pharmaceutical Industries
◍ LG Life Sciences
◍ Celltrion Biocon
◍ Hospira
◍ Merck
◍ Biogen idec
◍ Genentech (Roche)
◍ Pfizer
◍ Celltrion
◍ Biocon
◍ Amgen
◍ Samsung Biologics
◍ Mylan
◍ Dr. Reddy's Laboratories
◍ Stada Arzneimittel AG
The Bio Similars/Subsequent Entry Biologic Market is highly competitive with companies like Sun Pharma, Teva Pharmaceutical, Celltrion, Samsung Biologics, and AbbVie leading the market. These companies manufacture and distribute bio similars, helping to increase market competition and provide more affordable treatment options for patients.
- Sun Pharma: $4.4 billion
- Teva Pharmaceutical: $16.8 billion
- Celltrion: $1.1 billion
- Samsung Biologics: $889 million
◍ AbbVie
Request Sample Report
Market Segmentation
By Application By Product
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
◍ Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Request Sample Report
◍
◍
◍
◍
◍
◍
◍
◍
◍
◍
Market Growth
Request Sample Report
$ X Billion USD
THANK YOU Email : sales@reportprime.com USA : +1 507 500 7209 Website : https://www.reportprime.com/ Request Sample Report Contact US Our Clients